BibbInstruments

BibbInstruments Dluh/EBITDA

Poměr Celkového Dluhu k EBITDA společnosti BibbInstruments (BIBB.SL) k datu 19. 10. 2026.

Dluh/EBITDA

0,00

Poslední aktualizace:

Poměr Celkového Dluhu k EBITDA společnosti BibbInstruments je 2020 0,00 . Poměr Celkového Dluhu k EBITDA společnosti BibbInstruments byl 2019 0,00 . Klesá tak o % nižší než v předchozím roce.

Historie BibbInstruments Dluh/EBITDA

  • 3 roky

  • 10 let

  • 25 Let

  • Maximum

Dluh/EBITDA
Datum
Dluh/EBITDA
1. 1. 2014
0,00 SEK
1. 1. 2015
0,00 SEK
1. 1. 2016
0,00 SEK
1. 1. 2017
0,00 SEK
1. 1. 2018
0,00 SEK
1. 1. 2019
0,00 SEK
1. 1. 2020
0,00 SEK
Historie BibbInstruments Dluh/EBITDA
ROKDluh/EBITDAYoY
0,00—
0,00—
0,00—
0,00—
0,00—
0,00—
0,00—

Tato data přes Eulerpool API

100 000 požadavků/měs. zdarma · bez karty

BibbInstruments Analýza akcií

Co dělá BibbInstruments? BibbInstruments AB is a specialized medical technology enterprise headquartered in Lund, Sweden, operating within the health care sector. The company focuses on the development and marketing of advanced diagnostic instruments designed for the early detection of cancerous tumors. BibbInstruments went public on the Stockholm Stock Exchange on October 27, 2017, under the ticker symbol BIBB.SL, with the associated ISIN SE0010102095. Despite its technological focus, the organization maintains a lean operational structure, currently employing only four full-time staff members. The core of the company’s innovation lies in its proprietary technology platform known as EndoDrill. This platform utilizes a unique drill function that facilitates early cancer diagnosis, particularly within deep skin tissues and internal organs, offering a minimally invasive alternative to traditional biopsy methods. The product portfolio is diverse and tailored to specific medical needs across various bodily systems. It includes the EndoDrill GI Upper, which is engineered for stomach biopsies, and the EndoDrill GI Lower, designed for intestinal procedures. For respiratory diagnostics, the company offers the EndoDrill GI Lung for lung biopsies. Beyond diagnosis, the portfolio extends into therapeutic applications through the EndoDrill Therapy device, which allows for the passage of displacements in different organs to facilitate the placement of conductors, balloons, and stents for treatment purposes. Additionally, the EndoDrill Needle is available for breast biopsies, while the EndoDrill Model X serves multiple areas and is currently part of an independent research project. The company’s distribution strategy is primarily concentrated on Scandinavian countries, targeting hospitals equipped with endoscopy specialist centers and surgical wards. By focusing on these specific clinical environments, BibbInstruments aims to provide healthcare professionals with precise tools that enhance diagnostic accuracy and patient outcomes. The company’s website, https://www.bibbinstruments.com/, serves as the primary digital hub for information regarding its products and technological advancements. As a small but focused entity, BibbInstruments AB represents a niche player in the global medical device market, emphasizing innovation in early cancer detection through its specialized EndoDrill technology. BibbInstruments je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií BibbInstruments

Na Eulerpool najdete úplný historický vývoj Poměr Celkového Dluhu k EBITDA BibbInstruments od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Dluh/EBITDA měří celkový dluh v poměru k zisku před úroky, daněmi a odpisy. Ukazuje roky potřebné k splacení veškerého dluhu z EBITDA.

Dobrá hodnota se liší podle odvětví a fáze vývoje společnosti. Na Eulerpool můžete porovnat BibbInstruments společnosti Poměr Celkového Dluhu k EBITDA s porovnatelnými společnostmi a průměrem odvětví, abyste určili, zda je atraktivní.

Tato data přes Eulerpool API

100 000 požadavků/měs. zdarma · bez karty

Páka — BibbInstruments

Všechny klíčové ukazatele — BibbInstruments